CAR-T cell therapy for children with ALL and minimal residual disease
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment using the patient's own immune cells, modified to find and attack leukemia cells that remain after initial chemotherapy. It's for children with B-cell acute lymphoblastic leukemia who still have tiny amounts of cancer cells detectable after standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 1 and 18 years old and weighs at least 22 pounds (10 kg).
- After initial chemotherapy, a bone marrow test still finds a small number of leukemia cells (MRD-positive) on day 46.
- The leukemia cells have two markers called CD19 and CD22 on their surface.
- Your child's major organs (liver, kidneys, heart, lungs) are working well enough to handle the therapy.
- Your child has a performance score of at least 50 (Lansky) or 70 (Karnofsky), meaning they can do most daily activities.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies CAR-T cell therapy, a treatment that uses your own immune cells (T cells) trained to find and attack cancer cells, in people with a type of blood cancer called acute lymphoblastic leukemia (ALL) that has come back or hasn't gone away. The goal is to see how well these therapies work in both children and adults.
This trial tests a new CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) for people with B-cell acute lymphoblastic leukemia who have achieved their first complete remission after standard chemotherapy. The goal is to see if this therapy can keep the leukemia from coming back.
This early-phase trial tests CAR T-cells made to attack leukemia cells with specific markers (CD19 and CD22). It may help people with difficult-to-treat, relapsed, or high-risk acute lymphoblastic leukemia (ALL), especially when standard treatments haven’t worked well.
This trial tests a special immune cell treatment (CAR-T cells) for children whose leukemia or lymphoma has come back or not responded to at least two prior treatments. The goal is to see if these cells can find and destroy the cancer.
This trial tests a new type of immune therapy called CAR T-cells (engineered to find and attack a protein called CD19 on leukemia cells) for children whose acute lymphoblastic leukemia has come back or hasn't responded to usual treatments. The goal is to see if these special cells can safely help control the disease.
This trial tests a new type of immunotherapy called CAR-T cells, which are made from your own blood cells and trained to find and destroy leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.